ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered
ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…
CertaraJuly 23, 2025
The Reference-scaled Average Bioequivalence (RSABE) Approach
We examine the Reference-scaled Average Bioequivalence (RSABE) approach for generic drug development and how it…
CertaraJuly 1, 2025
5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address
June 30, 2025 Drug development is increasingly defined by its complexity. Teams must navigate rising…
CertaraJune 30, 2025
How Model-informed drug development rescue projects from a risky situation
Discover how Certara’s integrated approach to model-informed drug development helps clients navigate regulatory challenges, achieve…
CertaraJune 26, 2025
From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara
Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…
CertaraJune 18, 2025
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer
The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…
CertaraJune 8, 2025
